Mid-Con Energy Partners (MCEP) has seen its unit price fall around 30% since the beginning of June as oil prices have also fallen substantially during the past few weeks. I believe that Mid-Con could now nearly double from current levels, although there is significant risk involved. For Mid-Con to nearly double, it needs to avoid major difficulties with its credit facility lenders, start growing its production modestly again and also have the long-term price of oil go back up to around $50. While I believe that oil should generally gravitate to the $45 to $55 range over time, if oil is stuck at the low end of that range or below for the rest of 2017, that could cause problems for Mid-Con with its credit facility. Thus Mid-Con is both a bet on modestly higher long-term oil prices and a partial recovery that happens before October.
Limited Impact On Finances
Lower oil prices will only have a modest impact on Mid-Con’s finances during the rest of 2017. The difference between $44 oil (current strip) and $50 oil over the back half of 2017 for Mid-Con’s cash flow is around $1.4 million, as the decrease in oil revenue is significantly offset by hedges and production tax savings. Thus, Mid-Con’s credit facility borrowings are estimated to be a bit over $115 million at the end of 2017 based on strip prices now, versus $113.7 million when calculated from prices at the beginning of June.
automated stock trading: FibroGen, Inc(FGEN)
Advisors’ Opinion:
- [By WWW.THESTREET.COM]
The Good
The market remains resistant (Rs over Ss and Ns). Brokerages, banks and insurance companies continue their league-leading strength. The Russell 2000 Index is up for the 15th consecutive day. Retail extends yesterday’s strength. Nordstrom (JWN) , Macy’s (M) , Best Buy (BBY) , Target (TGT) , Walmart (WMT) , Foot Locker (FL) and JCPenney (JCP) are strong. First day down for Amazon (AMZN) . Agricultural commodities are lackluster, but soybeans are up another up $0.05 today, up substantially for three days in a row. Speculative biotech (Sage (SAGE) , FibroGen (FGEN) , Acadia Pharmaceuticals (ACAD) and Aerie Pharmaceuticals (AERI) ) stronger after recent weakness. Ag equipment up big time after the Deere (DE) beat.
The Bad
automated stock trading: Snap Inc. (SNAP)
Advisors’ Opinion:
- [By Virendra Singh Chauhan]
Shares of Menlo Park, California-based Facebook Inc. (NASDAQ:FB)have been on a solid run. FB stock closed the last trading session at a price of$139.92 per share, 0.8% lower than the previous close. While the stock is still up by nearly 22% for the year, the recent trade action saw the stock slip below a crucial support level. The closing price of$139.92 was the first time that FB stock closed below the $140 mark since March 23rd. On a more positive note, Facebook announced yet another shot aimed at Snap Inc (NYSE:SNAP) owned Snapchat. Having stepped up its battle against Snapchat with a flurry of strikes through its various social networks/communicationplatforms, the social networking giant delivered what could be the next major blow to Snap Inc (NYSE:SNAP) owned Snapchat. Given the mixed news around FB stock, should investors exit FB stock on the fall below an important support line? Or is this an opportunity to buy into a solid growth name, at lower valuation levels?
- [By Virendra Singh Chauhan]
Venice, California, based Snap Inc (NYSE:SNAP), parent of the popular photo-sharing app Snapchat has been listed on the NYSE for less than a week. In the week immediately following the Snap IPO, a number of Wall Street firms issued initial commentary on SNAP stock. And well, the Wall Street commentary has been far from encouraging for SNAP bulls. The latest to join this deluge of Wall Street chorus wasShebly Seyrafi fromFBN Securities, who believes that Facebook Inc (NASDAQ:FB) could be interested in buying out Snapchat. But Would the Menlo park, based Social Networking giant really consider making such a bid?
- [By Virendra Singh Chauhan]
Venice, California, based Snap Inc (NYSE:SNAP), owner of the popular photo sharing platform, ‘Snapchat’ has now been listed on the NYSE for a fortnight. The company’s life as a publicly listed company has been anything, but rosy. After opening at $24 on the IPO day, it has been all downhill for the newly listed company. Snap stock closed the last trading session at a price of $19.89, down over 17% from its IPO day open. This was also the first time the stock closed below the $20 mark following its IPO. With the SNAP stock price now approaching its IPO price of $17, what lies ahead for SNAP stock? Is it time to sell the stock? Or, have we hit the bottom?
- [By Jack Delaney]
After the March 2 Snap Inc. (NYSE: SNAP) IPO, anxious investors are waiting for the next big private company to go public. Retail investors assume they can make double-digit and triple-digit returns by buying into an IPO early.
- [By Virendra Singh Chauhan]
The life of Venice, California-basedSnap Inc. (NYSE:SNAP)as a public company can be best summarized as ‘short, volatile and eventful.’ SNAP stock hasseen huge volatility, rising from its IPO price of $17 to close its first trading day at $24.5 per share. After closing at a high of $27.09 on March 3rd, the stock fell all the way to sub-$20 levels before rising back to nearly $24. And, Snap stock price now hovers around the $20 mark, closing the last trading session at $20.8 per share (April 7). More importantly, the stock could fall below the psychologically crucial $20 mark, after multiple investment houses recently issued cautious to neutral commentary on the name.
automated stock trading: Lexaria Bioscience (LXRP)
Advisors’ Opinion:
- [By James E. Brumley]
Don’t be surprised if Lexaria Bioscience Corp (OTCMKTS:LXRP) shares seem a little peppier and even more bullish than usual for the next three months, give or take… and that’s saying something considering LXRP is 158% since early October, and up 47% since mid-December. Why’s that? The organization has hired a publicity firm to help tell its story to an even bigger audience, and that attention could attract a whole new batch of buyers for the stock.
Granted, the Lexaria Bioscience story is a compelling one to begin with.
If 2016 (and 2017 so far) were to be pegged with any major investment “themes,” cannabis would have to be it. Marijuana/hemp — cannabinoids, ultimately — was on the ballot for one reason or another in nine states this past November, and those pro-cannabis measures passed in eight of those votes. As such, cannabis is now legal for at least one reason in 26 states of the United States, and the movement is still gathering momentum.
And well it should. The recreational aspect of marijuana and cannabinoids aside, hemp (a form of cannabis plant that isn’t the kind of marijuana that provides a “high”) delivers a multitude of health benefits. Specifically, users of hemp oil find the plant-based oil improves immunity, improves cardiovascular health, moderates blood sugar, treats skin conditions, treats arthritis, inhibits osteoporosis, fights some mental disorders, and in some cases has been found to be an anti-cancer agent. Lexaria Bioscience is simply enhancing these benefits of hemp oil by enhancing the amount of hemp oil a human body can absorb when ingested.
Simply put, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. The key to the science is the fact that Lexaria Bioscience is able to combine cannabinoids with lipids — or fatty acids — at the molecular level. It matters, because the human endocannabinoid system is it
- [By Bryan Murphy]
When you’ve come up with a technology that increases the digestion of minerals, vitamins, compounds, nutrients, and even medicine, the first thing you want to do is protect that idea so nobody else can commercialize it except you. Well, Lexaria Bioscience Corp (OTCMKTS:LXRP) has figured out how to do the former, and it’s been doing the latter… in spades. First it started by building a wall around its platform in the United States, but as of today’s press release is building a wall internationally as well.
It’s an exciting prospect to be sure. In simplest terms, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.
It’s largely unrecognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.
Lexaria Bioscience changes the game, so to speak. How? A proprietary process that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.
The science: Lexaria Bioscience has defined a way to combine cannabinoids with lipids — or fatty acids — at the molecular level. It matters, because the human endocannabinoid system is itself lipid based, making this format the easiest and most effective means of introducing the medicinal and health benefits of hemp and hemp oil.
And the results have been impressive in two different studies
- [By Bryan Murphy]
Though they’re not the same thing, anything that’s good for marijuana is good for hemp. That’s why when eight out of nine states that had marijuana on the ballot two Tuesday’s ago approved those measures, things got a lot more compelling for owner of Lexaria Bioscience Corp (OTCMKTS:LXRP).
What’s the difference? Hemp a strains of Cannabis sativa that have been bred specifically for fiber used for clothing, construction, oils and topical ointments, nutritional benefits and a wide array of other purposes that don’t involve getting “high.” Marijuana is a slang term used to describe strains of Cannabis sativa that are bred for the potent resinous glands, or trichomes, that grow on the flowers and some leaves… the strain packed with tetrahydrocannabinol (or THC).
They would be easy to confuse, and commonly are. The potential for confusion, in fact, is the chief reason government agencies have been hesitant to support one and ban the other. With marijuana now legalized for use for one reason or another in more than half the United States though, knowledge and understanding of the difference will soon follow.
Great, but what’s that got to do with Lexaria Bioscience is on the leading edge of the movement of heightened understanding of what hemp is, and what it does.
The medical benefits of the non-psychoactive form of Cannabis sativa are impressive to say the least. Among other benefits, hempseed oil has also shown a positive effect on dermatological diseases and lipid metabolism (the process by which fatty acids are broken down in the body). Hempseed also has high levels of vitamins A, C and E and ?-carotene, and it is rich in minerals like phosphorus, potassium, magnesium, sulfur and calcium. As a food, hempseed oil is nutritious – it contains an excellent balance of polyunsaturated fatty acids – and it reportedly tastes good, too.
Problem: Hemp isn’t effectively absorbed into the body, and as such, it’s difficult to make effec
- [By Bryan Murphy]
In the grand scheme of things it shouldn’t be surprising, though odds are good at least a few people are surprised at how quickly it happened. That is, health supplement and healthy-foods brand name NeutriSci International Inc (CVE:NU) and the developer of a cannabis-infusion technology — a means of packing more CBD into hemp oil — called Lexaria Bioscience Corp (OTCMKTS:LXRP) have finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.
The benefits of cannabidiol, found in hemp and marijuana, are relatively well understood by the market at this point. Cannabidiol can do a human body a lot of good, like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more. Pterostilbene is the lesser-known of the two components of the new tablet, but no less impressive and no less beneficial. Pterostilbene is known to combat high cholesterol, high blood pressure, and oxidative stress. Combining the two is a real one-two punch for the health-conscious.
That’s what made November’s news so exciting… NeutriSci International has an established name and marketing channel, while Lexaria Bioscience has the science that makes hemp oil far more functional. Indeed, to fully appreciate the upside for LXRP, one has to embrace Lexaria’s science and why it matters.
The bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.
Lexaria Bioscience changes this. In short,
- [By Jim Robertson]
In October, small cap food sciences stockLexaria Bioscience Corp (OTCQB: LXRP) was issuedU.S. Patent No. 9,474,725 Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof and now the company is seeking to expand this patent internationally. This patent protects Lexaria Bioscience Corps intellectual property related to infusion of cannabinoid compounds in edible products and includes a set of claims that describe the Companys method of combining a fatty acid compound with any non-psychoactive cannabinoid for improved bioavailability and taste performance in both food and beverage formats.
automated stock trading: Lifetime Brands Inc.(LCUT)
Advisors’ Opinion:
- [By Lisa Levin]
On Monday, cyclical consumer goods & services shares gained by 0.41 percent. Top gainers in the sector included Kandi Technologies Group Inc (NASDAQ: KNDI), Starwood Hotels & Resorts Worldwide Inc (NYSE: HOT), and Lifetime Brands Inc (NASDAQ: LCUT).
automated stock trading: GSE Systems, Inc.(GVP)
Advisors’ Opinion:
- [By Jim Robertson]
On Thursday, our Under the Radar Moversnewsletter suggestedbuying small cap performance improvement stock GSE Systems (NYSEMKT: GVP):
GSE Systems is another somewhat-preemptive position; we think the recent support at the 100-day moving average line (gray) and subsequent string of higher lows is telling. There’s a ceiling at $3.27 that needs to be cleared, but we fear waiting on that to happen because once it does, GVP shares could be catapulted to a price we don’t want to chase.
automated stock trading: Diamondrock Hospitality Company(DRH)
Advisors’ Opinion:
- [By Monica Gerson]
DiamondRock Hospitality Company (NYSE: DRH) is projected to post its quarterly earnings at $0.18 per share on revenue of $218.42 million.
Weyerhaeuser Co (NYSE: WY) is expected to report its quarterly earnings at $0.20 per share.
